Inhibition of platelet aggregation by naproxen, rofecoxib, diclofenac, ibuprofen, and meloxicam

被引：0
|
作者：
Schwartz, JI
Van Hecken, A
De Lepeleire, I
Depre, M
Wong, P
Ebel, DL
Gertz, BJ
De Schepper, PJ
机构：
[1] Merck Res Labs, Clin Pharmacol, Rahway, NJ USA
[2] UZ Gasthuisberg, Ctr Clin Pharmacol, Louvain, Belgium
[3] Merck Human Hlth, Clin Pharmacol, Brussels, Belgium
[4] Merck Res Labs, CBARDS, Rahway, NJ USA
[5] Merck Human Hlth, Clin Res, Rahway, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2003年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：263 / 263
页数：1
相关论文
共 50 条
  • [1] Platelet aggregation inhibition by naproxen, rofecoxib, diclofenac, ibuprofen, and meloxicam
    Schwartz, JI
    Van Hecken, A
    De Lepeleire, I
    Depré, M
    Wong, PH
    Ebel, DL
    Gertz, BJ
    De Schepper, PJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (09): : 1035 - 1035
  • [2] Platelet aggregation inhibition by naproxen, rofecoxib, diclofenac, ibuprofen, and meloxicam.
    Schwartz, JI
    Van Hecken, A
    De Lepeleire, I
    Depre, M
    Wong, P
    Ebel, D
    Gertz, B
    De Schepper, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P53 - P53
  • [3] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers
    Van Hecken, A
    Schwartz, JI
    Depré, M
    De Lepeleire, I
    Dallob, A
    Tanaka, W
    Wynants, K
    Buntinx, A
    Arnout, J
    Wong, PH
    Ebel, DL
    Gertz, BJ
    De Schepper, PJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (10): : 1109 - 1120
  • [4] Use of antihypertensive therapy among new chronic persistent users of diclofenac, ibuprofen, naproxen and rofecoxib
    Langman, MJS
    Mavros, P
    Sen, SS
    Kong, SX
    Watson, DJ
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S121 - S121
  • [5] Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin
    Lanes, SF
    Rodríguez, LAG
    Hwang, E
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2000, 9 (02) : 113 - 117
  • [6] A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation
    Galliard-Grigioni, Katja S.
    Reinhart, Walter H.
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 609 (1-3) : 96 - 99
  • [7] Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac
    Hegi, TR
    Bombeli, T
    Seifert, B
    Baumann, PC
    Haller, U
    Zalunardo, MP
    Pasch, T
    Spahn, DR
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 2004, 92 (04) : 523 - 531
  • [8] Non-differential risk of anti hypertensive therapies among new chronic persistent users of diclofenac, ibuprofen, naproxen, or rofecoxib
    Langman, MJS
    Mavros, P
    Sen, SS
    Kong, SX
    Watson, DJ
    [J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S56 - S57
  • [9] Low-dose diclofenac, naproxen, and ibuprofen cohort study
    Pérez-Gutthann, S
    García-Rodríguez, LA
    Duque-Oliart, A
    Varas-Lorenzo, C
    [J]. PHARMACOTHERAPY, 1999, 19 (07): : 854 - 859
  • [10] Association between rofecoxib, diclofenac/ibuprofen and hospitalization for acute myocardial infarction
    Rahme, E
    Kong, SX
    Watson, DJ
    Toubouti, Y
    LeLorier, J
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 522 - 522
12345